Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight

Cuong Thach Nguyen, Yehudi Bloch, Katarzyna Składanowska, Savvas N. Savvides, Iannis Adamopoulos

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Psoriatic arthritis (PsA) is a chronic inflammatory arthritis of unknown etiology, and currently the cellular and molecular interactions that dictate its pathogenesis remain elusive. A role of the interleukin-23 (IL-23)/IL-23R (IL-23 receptor) interaction in the development of psoriasis and PsA is well established. As IL-23 regulates the differentiation and activation of innate and adaptive immunity, it pertains to a very complex pathophysiology involving a plethora of effectors and transducers. In this review, we will discuss recent advances on the cellular and molecular pathophysiological mechanisms that regulate the initiation and progression of PsA as well as new therapeutic approaches for IL-23/IL-23R targeted therapeutics.

Original languageEnglish (US)
JournalClinical Immunology
StateAccepted/In press - Jan 1 2018


  • Cytokines
  • Human monoclonal IL-23 antibodies
  • IL-23/IL-23R pathways
  • Psoriatic arthritis
  • Skin and joint inflammation
  • Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight'. Together they form a unique fingerprint.

Cite this